Literature DB >> 33479636

The synthesis and biological evaluation of sanguinarine derivatives as anti-non-small cell lung cancer agents.

Liang Jiang1, Xiaolu Wang1, Yuting Wang1, Fang Xu1, Zhang Zhang1, Ke Ding1, Xiaoyun Lu1.   

Abstract

A novel series of sanguinarine (SA) derivatives were synthesized and evaluated as anti-non-small cell lung cancer (NSCLC) agents. The compounds inhibited A549 and H1975 NSCLC cells with IC50 values of 0.96 - >30 μM and 0.79 - >30 μM, respectively. Compounds 8d-8j exhibited low micromolar inhibitory activity and indicated that the C6-position of SA was tolerated to be substituted by hydrophilic groups and CN. Further investigation of their mechanism of action showed that compound 8h induced apoptosis of A549 and H1975 cells by inhibiting the Akt signaling pathway and elevating the reactive oxygen species (ROS). This study provided a strategy for developing new anti-cancer agents. This journal is © The Royal Society of Chemistry 2020.

Entities:  

Year:  2020        PMID: 33479636      PMCID: PMC7489057          DOI: 10.1039/c9md00494g

Source DB:  PubMed          Journal:  RSC Med Chem        ISSN: 2632-8682


  18 in total

1.  Structural modification of sanguinarine and chelerythrine and their antibacterial activity.

Authors:  Fang Miao; Xin-Juan Yang; Le Zhou; Hai-Jun Hu; Feng Zheng; Xu-Dong Ding; Dong-Mei Sun; Chun-Dong Zhou; Wei Sun
Journal:  Nat Prod Res       Date:  2011-05       Impact factor: 2.861

2.  Transformation from NSCLC to SCLC: when did it happen? - Authors' reply.

Authors:  Jeffrey A Engelman; Matthew G Oser; Matthew J Niederst; Lecia V Sequist
Journal:  Lancet Oncol       Date:  2015-07       Impact factor: 41.316

Review 3.  Lessons To Be Learned: The Molecular Basis of Kinase-Targeted Therapies and Drug Resistance in Non-Small Cell Lung Cancer.

Authors:  Jonas Lategahn; Marina Keul; Daniel Rauh
Journal:  Angew Chem Int Ed Engl       Date:  2018-01-12       Impact factor: 15.336

Review 4.  Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer.

Authors:  C Hardin; E Shum; A P Singh; R Perez-Soler; H Cheng
Journal:  Expert Opin Pharmacother       Date:  2017-04-17       Impact factor: 3.889

5.  Visible-light-promoted iminyl-radical formation from acyl oximes: a unified approach to pyridines, quinolines, and phenanthridines.

Authors:  Heng Jiang; Xiaode An; Kun Tong; Tianyi Zheng; Yan Zhang; Shouyun Yu
Journal:  Angew Chem Int Ed Engl       Date:  2015-02-03       Impact factor: 15.336

Review 6.  AKT/PKB Signaling: Navigating the Network.

Authors:  Brendan D Manning; Alex Toker
Journal:  Cell       Date:  2017-04-20       Impact factor: 41.582

7.  Sanguinarine inhibits growth of human cervical cancer cells through the induction of apoptosis.

Authors:  Jia-Ying Xu; Qing-Hui Meng; Yu Chong; Yang Jiao; Lin Zhao; Eliot M Rosen; Saijun Fan
Journal:  Oncol Rep       Date:  2012-09-11       Impact factor: 3.906

8.  Pembrolizumab for the treatment of non-small cell lung cancer.

Authors:  Sung Hee Lim; Jong-Mu Sun; Se-Hoon Lee; Jin Seok Ahn; Keunchil Park; Myung-Ju Ahn
Journal:  Expert Opin Biol Ther       Date:  2016       Impact factor: 4.388

9.  Pharmacokinetic and anti-inflammatory effects of sanguinarine solid lipid nanoparticles.

Authors:  Weifeng Li; Huani Li; Huan Yao; Qingli Mu; Guilan Zhao; Yongmei Li; Hua Hu; Xiaofeng Niu
Journal:  Inflammation       Date:  2014-04       Impact factor: 4.092

10.  Targeting Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer by Inducing Epidermal Growth Factor Receptor Degradation via Methionine 790 Oxidation.

Authors:  Elaine Lai-Han Leung; Xing-Xing Fan; Maria Pik Wong; Zhi-Hong Jiang; Zhong-Qiu Liu; Xiao-Jun Yao; Lin-Lin Lu; Yan-Ling Zhou; Li-Fong Yau; Vicky Pui-Chi Tin; Liang Liu
Journal:  Antioxid Redox Signal       Date:  2015-12-14       Impact factor: 8.401

View more
  1 in total

1.  Synthesis and Antileukemia Activity Evaluation of Benzophenanthridine Alkaloid Derivatives.

Authors:  Yaling Tang; Xinglian Xu; Jiang Li; Lulu Deng; Shuzhen Mu
Journal:  Molecules       Date:  2022-06-19       Impact factor: 4.927

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.